RenovoRx, Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$10M
Investors
16
Min Invest
$10,000
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
RenovoRx, Inc. is a Delaware corporation that filed a Form D with the SEC on April 9, 2026 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. RenovoRx, Inc. reported $9,999,929 sold from 16 investors of a $10,000,000 total offering as of the Form D filed April 9, 2026. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $10,000. The Form D names T.R. WINSTON & COMPANY, LLC (CRD 10571), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $549,996 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 2570 W. El Camino Real, Ste. 320,, Mountain View, CA 94040.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
3
latest Apr 9, 2026
Critical / warning
0 / 0
0 watch · 3 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
5
lapsed, raising, closed
Latest event New filer · Apr 9, 2026
SEC.govInvestor
- 3 filing events with values and deltas, latest 2026-04-09, and alerts on the next one
- 5 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-04-09: 1 related person added and 1 removed against the filing of 2024-04-22; 8 now listed. The names are in the Terminal feed.
Shaun R. Bagai
Executive Officer, Director · MOUNTAIN VIEW, CA
Mark R. Voll
Executive Officer · MOUNTAIN VIEW, CA
Leesa R. Gentry
Executive Officer · MOUNTAIN VIEW, CA
Ramtin R. Agah
Executive Officer · MOUNTAIN VIEW, CA
Laurence J. Marton
Director · MOUNTAIN VIEW, CA
Una S. Ryan
Director · MOUNTAIN VIEW, CA
Kirsten Angela Macfarlane
Director · MOUNTAIN VIEW, CA
Robert J. Spiegel
Director · MOUNTAIN VIEW, CA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
T.R. WINSTON & COMPANY, LLCCRD 10571 on BrokerCheck
Associated broker-dealer: None · BEDMINSTER, NJ · Soliciting in all states
Questions About RenovoRx, Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is RenovoRx, Inc.?
RenovoRx, Inc. is a Delaware corporation that filed a Form D with the SEC on April 9, 2026 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.
Is RenovoRx, Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. RenovoRx, Inc. filed a Form D with the SEC on April 9, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $9,999,929 sold to 16 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is RenovoRx, Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that RenovoRx, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has RenovoRx, Inc. raised?
RenovoRx, Inc. reported $9,999,929 sold from 16 investors of a $10,000,000 total offering as of the Form D filed April 9, 2026.
Who can invest in RenovoRx, Inc.?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $10,000.
What is the minimum investment in RenovoRx, Inc.?
The Form D lists $10,000 as the minimum investment accepted from any outside investor as of April 9, 2026. Issuers can waive their own minimums, and the figure does not include fees.
Who is selling RenovoRx, Inc. and how are they paid?
The Form D names T.R. WINSTON & COMPANY, LLC (CRD 10571), associated with None as the recipient of sales compensation soliciting in all states. Sales commissions are reported as $549,996 and finders' fees as $0. Form D allows these to be estimates.
Who is behind RenovoRx, Inc.?
The Form D lists 8 related persons: Shaun R. Bagai, executive officer, director; Mark R. Voll, executive officer; Leesa R. Gentry, executive officer; Ramtin R. Agah, executive officer; Laurence J. Marton, director; Una S. Ryan, director; Kirsten Angela Macfarlane, director; Robert J. Spiegel, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is RenovoRx, Inc. located?
The issuer's address on its SEC filings is 2570 W. El Camino Real, Ste. 320,, Mountain View, CA 94040. Its phone number of record is 408-800-2649. It is organized under the laws of Delaware.
How long is the RenovoRx, Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is RenovoRx, Inc.'s revenue?
The Form D reports a revenue range of $1,000,001 - $5,000,000.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
